Cytosolic phospholipase A2 protein as a novel therapeutic target for spinal cord injury
Article first published online: 2 APR 2014
© 2014 The Authors. American Neurological Association
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Annals of Neurology
Volume 75, Issue 5, pages 644–658, May 2014
How to Cite
Liu, N.-K., Deng, L.-X., Zhang, Y. P., Lu, Q.-B., Wang, X.-F., Hu, J.-G., Oakes, E., Bonventre, J. V., Shields, C. B. and Xu, X.-M. (2014), Cytosolic phospholipase A2 protein as a novel therapeutic target for spinal cord injury. Ann Neurol., 75: 644–658. doi: 10.1002/ana.24134
- Issue published online: 10 JUN 2014
- Article first published online: 2 APR 2014
- Accepted manuscript online: 13 MAR 2014 12:21AM EST
- Manuscript Accepted: 10 MAR 2014
- Manuscript Revised: 28 FEB 2014
- Manuscript Received: 13 AUG 2013
The objective of this study was to investigate whether cytosolic phospholipase A2 (cPLA2), an important isoform of PLA2 that mediates the release of arachidonic acid, plays a role in the pathogenesis of spinal cord injury (SCI).
A combination of molecular, histological, immunohistochemical, and behavioral assessments were used to test whether blocking cPLA2 activation pharmacologically or genetically reduced cell death, protected spinal cord tissue, and improved behavioral recovery after a contusive SCI performed at the 10th thoracic level in adult mice.
SCI significantly increased cPLA2 expression and activation. Activated cPLA2 was localized mainly in neurons and oligodendrocytes. Notably, the SCI-induced cPLA2 activation was mediated by the extracellular signal-regulated kinase signaling pathway. In vitro, activation of cPLA2 by ceramide-1-phosphate or A23187 induced spinal neuronal death, which was substantially reversed by arachidonyl trifluoromethyl ketone, a cPLA2 inhibitor. Remarkably, blocking cPLA2 pharmacologically at 30 minutes postinjury or genetically deleting cPLA2 in mice ameliorated motor deficits, and reduced cell loss and tissue damage after SCI.
cPLA2 may play a key role in the pathogenesis of SCI, at least in the C57BL/6 mouse, and as such could be an attractive therapeutic target for ameliorating secondary tissue damage and promoting recovery of function after SCI. ANN NEUROL 2014;75:644–658